Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q2 2021 Results - Earnings Call Transcript
04:26pm, Wednesday, 28'th Jul 2021
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q2 2021 Results - Earnings Call Transcript
Will Roche's Stock Rebound After A 4% Fall Following Its H1 Results?
10:00am, Tuesday, 27'th Jul 2021
The stock price of Roche Holding's ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much
Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results - Earnings Call Transcript
07:55pm, Thursday, 22'nd Jul 2021
Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results - Earnings Call Transcript
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
01:31pm, Thursday, 22'nd Jul 2021
Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer's disease drug candidate, gantenerumab. CEO Severin Schwan declined to speculate on the outcome of the talks, Re
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
12:14pm, Thursday, 22'nd Jul 2021
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says
06:48am, Thursday, 22'nd Jul 2021
Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enou
Roche CEO: Very Confident Will Reach Our Outlook
04:41am, Thursday, 22'nd Jul 2021
Jul.22 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses company earnings, the outlook for covid tests in the second half of the year and the timeline for the firm's covid anti
Covid testing demand is on the decline, Roche CEO says
04:01am, Thursday, 22'nd Jul 2021
Roche CEO Severin Schwan discusses the pharmaceutical company's second-quarter earnings, the outlook for Covid-19 testing in the second half of the year, and treatments in the pipeline.
Roche keeps outlook as diagnostics power sales growth
01:16am, Thursday, 22'nd Jul 2021
Roche posted first-half net profit of 8.22 billion Swiss francs ($8.96 billion) as sales rose 8% at constant exchange rates to a better-than expected 30.71 billion francs.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results
01:00am, Thursday, 22'nd Jul 2021
Basel, 22 July 2021
15 European Dividend Aristocrats to Diversify Your Portfolio
01:47pm, Wednesday, 21'st Jul 2021
Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
05:59am, Wednesday, 21'st Jul 2021
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with myelodysplastic syndromes (MDS). Ven
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Venclexta® (venetoclax) in combination with azacitidine has bee
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
01:00am, Tuesday, 20'th Jul 2021
Basel, 20 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve™(casirivimab and imdevimab), for the treatm
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
08:18am, Monday, 19'th Jul 2021
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A treatment Hemlibra. The new safety data f
